API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 7 sources · 7 days · First seen · Last updated

Pharmaceutical industry licensing and expansion

Overview

The pharmaceutical sector has seen significant investment and licensing activity. AbbVie is expanding its research and development operations in Oxford, UK, by establishing a new 12,000 square foot facility as part of a broader £120 million commitment to the UK life sciences sector. Additionally, AbbVie has signed an exclusive global licensing agreement with Japan-based Nxera, valued at up to $1.37 billion, to develop a treatment for inflammatory bowel disease.

In a separate major transaction, Novartis has entered into a licensing and options agreement with China-based Abogen Biosciences. This deal is valued at up to $7.8 billion, including a $575 million upfront payment and milestone-based conditional payments. Through this agreement, Novartis secures worldwide exclusive rights to the mRNA-encoded T-cell engager ABO2203 and options for future programs on Abogen’s mRNA platform to treat B-cell mediated autoimmune diseases.

Entities

Nxera · European Union · AbbVie · Ministry of Internal Affairs · Oxford

Timeline

  1. [BUSINESS] 5 sources
    Novartis to license mRNA therapies from Abogen in $7.8 billion deal

    Novartis has signed a deal worth up to $7.8 billion with Abogen Biosciences to license mRNA-based therapies for autoimmune diseases.

  2. [BUSINESS] 2 sources
    AbbVie expands Oxford research facility and signs $1.37 billion drug deal

    AbbVie is expanding its Oxford R&D facility as part of a £120 million UK investment and has signed a $1.37 billion licensing deal with Japan's Nxera for an inflammatory bowel disease treatment.

Sources

capitalul.ro · forbes.ro · healthcaremea.com · labnews.co.uk · mediafax.ro · ponturifierbinti.com · radiovacanta.ro